PRESS-RELEASE filed May 14, 2026 at 07:01 ET
Invivyd reported Q1 2026 PEMGARDA revenue of $13.7M (+22% YoY), beating consensus estimates on both revenue ($13.7M vs $18.1M expected) and EPS (-$0.04 vs -$0.08 expected). The company highlighted continued in vitro neutralizing activity against the BA.3.2.2 variant, IDMC recommendation to reduce post-dose monitoring time for VYD2311, and a strong cash position of $184.2M providing runway through the DECLARATION data readout in Q3 2026. However, net loss widened to $41.4M from $16.3M a year ago due to increased R&D spending on the DECLARATION trial, and the company raised ~$20M via ATM in April.